BiotechTube
Home/Atonco/Sylvain FANIER
SF

Sylvain FANIER

CEO

Atonco

Therapeutic Areas

Oncology

Atonco Pipeline

DrugIndicationPhase
Astatine-211-labeled anti-CAIX antibody (girentuximab)Non-Muscle Invasive Bladder Cancer (NMIBC), refractory to BCG/chemotherapyPre-clinical

Leadership Team at Atonco

JC
Jean-François CHATAL
Chief Medical Officer
JB
Jacques BARBET
Chief Scientific Officer
A(
Alexandra (GITEAU) PAILLARD
COO
CM
Clément MAYEUR
Chief Financial Officer
AR
Adrien REYMOND
Business Development Director
DB
Denis BILODEAU
Clinical Research Developer
View full Atonco profile